Understanding CGRP and Its Role in Migraines
CGRP is a neuropeptide involved in the transmission of pain and the dilation of blood vessels in the brain. During a migraine attack, CGRP levels are elevated, contributing to inflammation and hypersensitivity of the trigeminal nerve — one of the key pathways involved in migraine pathophysiology. This has made CGRP a prime target for researchers aiming to develop migraine-specific therapies.
The introduction of CGRP inhibitors over the past decade, including monoclonal antibodies like erenumab, fremanezumab, and galcanezumab, represented a major advancement in migraine treatment. These biologics specifically target either the CGRP ligand or its receptor, blocking its action and thereby preventing the onset of migraine attacks. While effective, they require monthly or quarterly injections and come with high costs.
The Breakthrough: A New Generation of CGRP Inhibitor
The breakthrough CGRP inhibitor featured in the recent clinical trial, currently identified by its investigational code (e.g., “TRV-123”…